"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle â€“ every drug that FDA approves â€“ carries some risk. One of the first lines of defense against "...
PANCRECARB® (pancrelipase) Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres are indicated for patients with exocrine pancreatic enzyme insufficiency such as: cystic fibrosis, chronic pancreatitis due to alcohol use or other causes, post-pancreatectomy and post-gastrointestinal bypass surgery (e.g. Billroth II gastroenterostomy).
DOSAGE AND ADMINISTRATION
Dosing, Duration Of Therapy
Dosage should be individualized and adjusted according to fat intake, severity of steatorrhea and the severity of the exocrine pancreatic insufficiency. Begin therapy with one or two capsules with meals or snacks and adjust dosage according to symptoms. Dose increases, if required, should be made slowly, with careful monitoring of response and symptomatology. It is important to ensure adequate hydration of patients at all times while taking PANCRECARB® (pancrelipase) . Patients with pancreatic enzyme insufficiency should consume a high-caloric diet with unrestricted fat intake, which is appropriate for age and clinical symptomology.
PANCRECARB® (pancrelipase) are supplied as follows:
PANCRECARB® (pancrelipase) MS-4 (clear, hard gelatin capsule imprinted in blue with "DCI" and "PANCRECARB® (pancrelipase) MS-4") in bottles of 100 (NDC 59767-002-01).
PANCRECARB® (pancrelipase) MS-8 (clear, hard gelatin capsule imprinted in blue with "DCI" and "PANCRECARB® (pancrelipase) MS-8") in bottles of 100 (NDC 59767-001-01).
PANCRECARB® (pancrelipase) MS-16 (clear, hard gelatin capsule imprinted in blue with "DCI" and "PANCRECARB® (pancrelipase) MS-16") in bottles of 100 (NDC 59767-003-01).
Store at controlled room temperature 25ºC (77ºF) in a dry place. Do not refrigerate. Do not expose capsules to humid air. Keep bottle tightly closed. Dispense capsules in a tight container.
Manufacturer information. n/a. FDA rev date: n/a
Last reviewed on RxList: 1/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Pancrecarb Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.